Crossmark

Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis

Crossref DOI link: https://doi.org/10.1016/j.arbres.2020.06.021

Published Print: 2020-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Yamasaki, Masahiro

Matsumoto, Naoko

Nakano, Shota

Kawamoto, Kazuma

Taniwaki, Masaya

Izumi, Yusuke

Otohara, Masaya

Nabeshima, Shinji

Ohashi, Nobuyuki

Hattori, Noboru
License Information

Text and Data Mining valid from 2020-12-01
More Information

This article is maintained by: Elsevier

Article Title: Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis

Journal Title: Archivos de Bronconeumología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arbres.2020.06.021

Content Type: simple-article

Copyright: © 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.